Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 300Carcinoma, Non-Small-Cell Lung 80Squamous Cell Carcinoma of Head and Neck 59Carcinoma, Renal Cell 58Neoplasms 40Neoplasm Metastasis 36Colorectal Neoplasms 36Stomach Neoplasms 29Carcinoma, Merkel Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 28Carcinoma, Transitional Cell 27Uterine Cervical Neoplasms 24Skin Neoplasms 24Head and Neck Neoplasms 24Lung Neoplasms 22Breast Neoplasms 21Carcinoma, Hepatocellular 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 18Pancreatic Neoplasms 16Uveal Melanoma 14Small Cell Lung Carcinoma 14Sarcoma 14Urinary Bladder Neoplasms 12Lymphoma 11Kidney Neoplasms 11Endometrial Neoplasms 11Brain Neoplasms 11Prostatic Neoplasms 10

Interventions

pembrolizumab 1binimetinib 1Vemurafenib 1Pharmaceutical Preparations 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × pembrolizumab × Dermatologic × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡